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Microwave-assisted RCM for the synthesis of carbocyclic
peptides
ANDREA J. ROBINSON,* JOMANA ELARIDI, BIANCA J. VAN LIEROP, SELMA MUJCINOVIC and W. ROY JACKSON
School of Chemistry, Monash University, Clayton 3800, Victoria, Australia
Received 9 December 2006; Revised 9 January 2007; Accepted 10 January 2007
Abstract: Microwave irradiation dramatically improves the efficiency of ring closing metathesis (RCM) reactions of resin-attached
peptides and the technology is illustrated by the highly selective synthesis of dicarba analogues of α-conotoxin IMI. Copyright 
2007 European Peptide Society and John Wiley & Sons, Ltd.
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Disulphide bridges are metabolically and chemically
unstable structural features in many naturally occur-
ring and synthetic peptides. Replacement of cystine
by the dicarba isostere (S,S)-2,7-diaminosuberic acid
((S,S)-2,7-diamino octanedioic acid) [1–3] has been
used to increase the metabolic stability in vaso-
pressin [4], natriuretic β-ANP [5], oxytocin [6–8], cal-
citocin [9], bradykinin antagonists [10] and haema-
toregulatory peptides [11]. We have recently reported
the synthesis of dicarba analogues of the cystine-
containing octapeptides octreotide, vapreotide and lan-
reotide using a single pot, on-resin, tandem ruthenium-
catalysed ring closing metathesis (RCM) followed by
rhodium-catalysed hydrogenation (Scheme 1) [12,13].
Although high purity products were obtained, vari-
able yields of products were isolated and the RCM
reactions required high catalyst loadings (20 mol%
first-generation Grubbs’ catalyst) and long reaction
times (48–96 h). In this communication, we report
that microwave irradiation accelerates RCM reactions of
resin-attached peptides resulting in quantitative cycli-
sation under lower catalyst loadings (5–10 mol%) and
much shorter reaction times (1–2 h).
α-Conotoxin IMI 1 is a disulphide-rich peptide iso-
lated from the venom of the vermivorous conus species
Conus imperialis [14]. The microwave-accelerated catal-
ysis is illustrated with the synthesis of two dicarba-
cystino hybrid CTx-IMI analogues, bicyclic peptides 2
and 3 (Figure 1). Native α-conotoxins are amidated at
HydrogenationRing Closing
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Scheme 1 Catalytic sequence for dicarba bridge formation.
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their C-termini. Rink amide resin was therefore chosen
to facilitate linear peptide construction and generate
the required C-terminal carboxamide upon resin cleav-
age. Standard SPPS using HATU-NMM activation and
Fmoc-protected amino acids were used to construct
the two linear peptides 4 and 5 (Scheme 2). Both of
these sequences possess two strategically placed non-
proteinaceous L-allylglycine (Hag) residues to facilitate
construction of the dicarba bridge. Intermediates were
carried through without purification or characterisation
up to the dodecapeptides 4 and 5. A sample of each
linear peptide was obtained by cleavage from the resin
and determined to be of >95% purity by reverse-phase
analytical chromatography. Mass spectral analysis gave
molecular ion peaks at m/z 783.5 [1/2(M + 2H)+] and
805.4 [1/2(M + 2HCOO)+], which are consistent with
the structures of the isomeric side chain de-protected
linear peptides 4 and 5.
Microwave irradiation of a mixture of Rink amide
bound-peptide 4 and second-generation Grubbs’ cat-
alyst (6, 10 mol%) in DCM containing 10% LiCl in
DMF [7,8] resulted in complete ring closure in only
1 hour [15,16]. Complete conversion could also be
achieved using a 5 mol% loading of catalyst and 2 h
of microwave irradiation. Mass spectral analysis of the
product mixture showed the required molecular ion
with m/z 769.4 [1/2(M + 2H)+] for the TFA-cleaved,
unsaturated [2,8] -dicarba peptide7 and no starting lin-
ear peptide. Analogous reaction conditions also resulted
in a complete cyclisation of 5 to the isomeric [3,12]
-dicarba analogue 8 (Scheme 2). Fmoc-de-protection
followed by aerial oxidation of resin-cleaved 7 and
8 in 10% DMSO/aqueous (NH4)2CO3 (0.1 M. pH 8)
then afforded the unsaturated cystino-dicarba CTx-IMI
analogues 9 and 10, respectively (Figure 2). Each pep-
tide was obtained in 25% crude yield and purified
by reverse-phase preparative chromatography (>99%
purity).
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Figure 1 Conus imperialis, α-CTx IMI 1 and carbocyclic analogues 2 and 3.
Ru
PCy3
PCy3
Cl
Cl Ph
Ru
PCy3
Cl
Cl Ph
NN MesMes
Fmoc-Gly-Hag-Cys-Ser-Asp-Pro-Arg-Hag-Ala-Trp-Arg-Cys-NH
STrt STrt
STrt STrt
STrt STrt
STrt STrt
STrt STrt
Fmoc-Gly-Cys-Hag-Ser-Asp-Pro-Arg-Cys-Ala-Trp-Arg-Hag-NH
STrt STrt
2
4 5
7 8
3
11 12
a
b
c
a
b
c
Fmoc-Gly-Hag-Cys-Ser-Asp-Pro-Arg-Hag-Ala-Trp-Arg-Cys-NH
Fmoc-Gly-Hag-Cys-Ser-Asp-Pro-Arg-Hag-Ala-Trp-Arg-Cys-NH
Fmoc-Gly-Cys-Hag-Ser-Asp-Pro-Arg-Cys-Ala-Trp-Arg-Hag-NH
Fmoc-Gly-Cys-Hag-Ser-Asp-Pro-Arg-Cys-Ala-Trp-Arg-Hag-NH
13 6
Scheme 2 Reagents and conditions: Rink amide resin (ž, 0.52 mmol/g loading). (a) 5–10 mol% second-generation Grubbs’
catalyst, DCM-10% 0.4 M LiCl/DMF, rt → 100 °C, 1–2 h, microwave irradiation; (b) Rh(I)(PPh3)3Cl, 80 psi H2, rt, 10% MeOH in
DCM, 14 h; (c) Fmoc-de-protection and resin cleavage.
Hydrogenation of carbocycles 7 and 8 in 10% MeOH-
DCM using sulphur-tolerant Wilkinson’s catalyst and
low hydrogen pressure (80 psi) facilitated quantitative
reduction at room temperature to give resin-bound pep-
tides 11 and 12 (Scheme 2). Interestingly, the resin-
cleaved crude product from each of these reactions
existed in the oxidised form (2, 3).
Significantly, attempted RCM reactions without
microwave irradiation were less successful. Exposure
of peptide 4 to the first-generation Grubbs’ catalyst
13 (50 mol%) in DCM at 50 °C for 72 h gave only
trace amounts (<10%) of cyclised product 7. While
RCM progressed further (∼70%) using the more reactive
second-generation Grubbs’ catalyst 6, conditions could
not be found to affect full cyclisation to 7 even under
high catalyst loading (50 mol%). Changes in solvent,
catalyst loading and reaction time had no positive effect
on conversion. The addition of chaotropic salts to the
reaction medium to disrupt aggregation also had no
effect on RCM yield. Similarly, RCM of a dicrotylglycine
analogue of the primary sequence of 4, which avoids
catalytic cycling through an unstable ruthenium-
methylidene species [17] and could be expected to give a
higher yield, also failed to achieve a complete conversion
to the cyclic target 7.
Construction of the isomeric [3,12]-dicarba CTx-IMI
8 was found to be even more problematic under
conventional heating conditions. Exposure of the resin-
bound peptide 5 to both first- and second-generation
Grubbs’ catalysts under a variety of experimental
conditions failed to yield the unsaturated carbocycle
8. Possible reasons for the poor reactivity of 5
included the diminished influence of the proline residue
in assisting the formation of the larger carbocycle
(32-membered ring), and the close proximity of the
C-terminal allylglycine residue to the bulky Rink amide
linker. The sequence was subsequently reconstructed
on BHA-resin bearing a linear HMBA-Gly-Gly linker
(Exposure of HMBA-linked peptides to ammonia vapour
causes cleavage and the generation of C-terminal
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Figure 2 Unsaturated [2,8]- and [3,12]-dicarba-α-CTx IMI analogues.
carboxamides). Cyclisation of the BHA resin-bound
peptide was attempted in the presence of 20 mol% of
second-generation Grubbs’ catalyst 6 and chaotrophic
salts, but mass spectral analysis of the product mixture
again showed only the starting peptide 5.
Hence, the microwave-assisted RCM methodology,
described above, provides a highly efficient, on-resin
route to carbocyclic peptides with quantitative con-
versions, fast reaction times (typically 1–2 h), high
resin loadings and lower Grubbs’ catalyst loading
(5–10 mol%). Importantly, the use of a dielectric heat-
ing facilitates the RCM of sequences that are other-
wise completely inert to cyclisation under conventional
heating methods [18]. Cystine-dicarba hybrids of bio-
logically active cyclic peptides, such as those described
above, can serve as useful probes for the delineation of
functional (redox active) and structural roles of native
disulphide bonds. Significantly, the on-resin homoge-
neous catalytic protocol, described in this paper, can
be used to generate these analogues. Conotoxins are
currently attracting widespread interest and are being
assessed as therapeutic agents for the treatment of
cancer, stroke, epilepsy and also the control of pain
[19]. The biological activity of the cystine-dicarba CTx-
IMI analogues 2, 3, 9 and 10, described herein, is
currently being examined and will be reported in due
course.
EXPERIMENTAL
Peptide Materials and Procedures
Peptides were synthesised in polypropylene Terumo syringes
(10 ml) fitted with a polyethylene porous (20 µm) frit. Solid
phase peptide synthesis (SPPS) was performed using a Visprep
SPE DL 24-port model vacuum manifold supplied by Supelco.
Coupling reactions and cleavage mixtures were shaken on a
KS125 basic KA elliptical shaker, supplied by Labortechnik at
400 motions per minute. Cleaved peptides were centrifuged on
a Hermle Z200A centrifuge, supplied by Medos at a speed of
4500 cycles per minute. General SPPS procedure: Peptides
were prepared using the general Fmoc-SPPS methodology on
Rink amide resin. After synthesis of the linear peptide, a small
aliquot was subjected to TFA cleavage. In a fritted syringe, Rink
amide resin was washed with DCM (7 ml, 3 × 1, 1 × 60 min)
and DMF (7 ml, 3 × 1, 1 × 30 min) and de-protected with 20%
piperidine in DMF (7 ml, 1 × 1, 2 × 10 min) and washed again
with DMF (7 ml, 5 × 1 min). NMM (6 equiv.) was added to
a solution of the protected amino acid and Fmoc-Xxx-OH
(3 equiv.) and HATU (2 equiv.) in DMF (3 ml) and shaken
gently for 1 min. The activated amino acid solution was added
to the resin-tethered amino acid and shaken gently for the
reported period of time. At the end of the reaction period,
the resin-peptide was washed with DMF (7 ml, 3 × 1 min), de-
protected with 20% piperidine in DMF (7 ml, 1 × 1, 2 × 10 min)
and washed again with DMF (7 ml, 5 × 1 min). The above
procedure was repeated until the desired peptide sequence was
constructed. The quantity of amino acids (3 equiv.), coupling
agents HATU (2 equiv.) and NMM (6 equiv.) remained constant
throughout the synthesis. After coupling the final amino acid,
the resin-peptide was washed with DMF (7 ml, 3 × 1 min),
DCM (7 ml, 3 × 1 min), MeOH (7 ml, 3 × 1 min) and dried on
the SPPS manifold for 1 h. General cleavage procedure: A
small aliquot of the resin-peptide (∼1 mg) was added to the
cleavage solution (5 ml, 90% TFA: 5% thioanisole: 2.5% EDT:
2.5% water and phenol, 1.6 g/5 ml of cleavage solution) and
shaken gently for 1.5 h. The mixture was then filtered and
the resin beads were rinsed with TFA (3 × 1 ml). The filtrate
was concentrated with a constant stream of air to yield oil.
The peptide was precipitated with ice-cold Et2O (2 ml) and the
mixture was centrifuged (3 × 10 min). The supernatant liquid
was decanted and the resultant residue was collected and
analysed by RP-HPLC and mass spectroscopy.
Catalytic Materials and Procedures
Tricyclohexylphosphine[1,3-bis(2,4,6-trimethylphenyl)-4,5
-dihydroimidazol-2-ylidene]-(benzylidene)ruthenium(II) dichlo-
ride (second-generation Grubbs’ catalyst) and tris(triphenyl-
phosphine) rhodium(I) chloride (Wilkinson’s catalyst,
Rh[(PPh3)3Cl]) were used as supplied by Aldrich and stored
under argon in a dry box. Argon and hydrogen were supplied
by BOC gases and were of high purity (<10 ppm oxygen).
Additional purification was achieved by passage of the gases
through water, oxygen and hydrocarbon traps. DCM, MeOH
and lithium chloride in DMF (LiCl/DMF), used for metal-
catalysed reactions, were de-gassed with high purity argon
prior to use.Microwave-assisted RCM procedure:Microwave
reactions were carried out on a Personal Chemistry (now
Biotage) Smith Synthesiser. The instrument produces a con-
tinuous focussed beam of microwave irradiation at 2.45 GHz
with a maximum power delivery of 300 W, which reaches and
maintains a selected temperature (100 °C). Reactions were per-
formed in high-pressure quartz microwave vessels fitted with
self-sealing Teflon septa as a pressure relief device, which
were crimped in place. The vessels contained magnetic stirrer
beads and the pressure and temperature of each reaction was
monitored continuously with an inbuilt pressure transducer
(located in the lid) and infrared pyrometer, respectively. Reac-
tion times were measured from the time the microwave began
heating until the reaction period had elapsed (cooling peri-
ods were not inclusive). In a dry box, a high-pressure quartz
microwave vessel was loaded with resin-peptide, catalyst and
solvent (DCM and LiCl/DMF). The vessel was capped and irra-
diated at 100 °C for 1 h. At the end of the reaction period, the
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resin-peptide was washed with DMF (3 ml, 3 × 1 min), DCM
(3 ml, 3 × 1 min) and MeOH (3 ml, 3 × 1 min) and dried on
the SPPS manifold for 1 h. A small aliquot of resin-peptide
(∼1 mg) was subjected to the TFA-mediated cleavage proce-
dure and the isolated peptide was analysed by RP-HPLC and
mass spectroscopy. Metathesis experiments are described in
the following format: resin-peptide (mg), solvent (ml), catalyst,
reaction temperature (°C) and reaction time (h). Wilkinson’s
hydrogenation procedure: In a dry box, a Fischer-Porter
tube was charged with substrate, Wilkinson’s catalyst and
dry deoxygenated solvent (10% MeOH/DCM). The apparatus
was connected to a hydrogenation manifold and purged three
times using a vacuum and an argon flushing cycle before
being pressurised with hydrogen gas to the reported pressure.
The reaction was then stirred at ambient temperature for the
reported reaction time. The hydrogen gas was vented and the
mixture was then filtered, washed with DCM (3 ml, 3 × 1 min),
MeOH (3 ml, 3 × 1 min) and dried on the SPPS manifold for
1 h. A small aliquot of resin-peptide (∼1 mg) was subjected to
the TFA-mediated cleavage procedure and the isolated peptide
was analysed by RP-HPLC and mass spectroscopy. Analyt-
ical liquid chromatography-mass spectrometry (LC-MS) was
conducted on a Gilson (Middleton, USA) instrument equipped
with a Gilson 215/819 injector module, 306 gradient pumps
and an Agilent 1100 diode array detector. Analysis was per-
formed on a Phenomenex Luna 5-µm C8(2) analytical column
(50 × 3 mm) using a gradient of 10–60% MeOH (0.1% formic
acid) at a flow rate of 1.1 ml min−1 for 10 min. Peptides
were detected with UV irradiation between 200 and 300 nm
and a Micromass (Manchester, UK) ZMD mass spectrometer
in positive electrospray ionisation (ESI+) mode. Inlet flow to
the source was restricted with a flow splitter (100 µl min−1)
and the entire instrument was controlled by MassLynx v3.5
software (Micromass). Peptide purification was performed by
reverse-phase high performance liquid chromatography (RP-
HPLC) on the Gilson/Micromass LC-MS instrument described
above, equipped with a Gilson FC 405 fraction collector that
was triggered by mass detection in the ESI Source. All runs
were performed on a Phenomenex Luna 5-µm C8(2) preparative
column (50 × 21.2 mm) using a solvent gradient of 10–60%
MeOH (0.1% formic acid) at a flow rate of 10 ml min−1 for
15 min. The flow to the detectors was reduced with an LC
Packing (San Francisco, USA) post-column splitter. Peptides
were detected by ESI-MS with the doubly charged ion used as
the collection trigger.
[2,8]-Dicarba-[3,12]-Cystino Conotoxin
Transformations Linear[2,8]-Hag-[3,12]-Cys
Conotoxin IMI
Fmoc-Gly-Hag-Cys-Ser-Asp-Pro-Arg-Hag-Ala-Trp-Arg-
Cys-NH2 4. The linear peptide 4 was synthesised using
the general SPPS procedure outlined above with Rink amide
resin (740 mg, loading 0.52 mmol g−1, 0.39 mmol), NMM
(255 µl, 2.31 mmol, 6 equiv.), the protected C-terminal amino
acid, Fmoc-L-Cys(Trt)-OH (676 mg, 1.15 mmol, 3 equiv.)
and HATU (293 mg, 0.77 mmol, 2 equiv.) in DMF (3 ml).
The mixture was gently shaken for 2.5 h. At the end of
the reaction period, the resin-peptide was washed with
DMF (7 ml, 3 × 1 min), de-protected with 20% piperidine
in DMF (7 ml, 1 × 1, 2 × 10 min) and washed again with
DMF (7 ml, 5 × 1 min). The above procedure was repeated
until the desired peptide sequence was constructed. A small
aliquot of the resin-peptide (∼1 mg) was subjected to the
TFA-mediated cleavage procedure and mass spectral anal-
ysis confirmed the formation of the linear conotoxin ana-
logue 4. Mass spectrum (ESI+, MeCN/H2O): m/z 783.5
[1/2(M + 2H)]+, 1/2(C71H98N20O17S2); m/z 1565.7 (M + H)+,
C71H97N20O17S2. LC-MS (Luna C8 RP-column, 10–60% MeOH
and 0.1% formic acid): tR = 8.86 min.
[2,8]-Dicarba-[3,12]-Cys Conotoxin IMI
Fmoc-Gly-c[Hag-Cys-Ser-Asp-Pro-Arg-Hag]-Ala-Trp-Arg-
Cys-NH2 7. The linear Fmoc-Gly-Hag-Cys(Trt)-Ser(OtBu)-
Asp(OtBu)-Pro-Arg(Pbf)-Hag-Ala-Trp(Boc)-Arg(Pbf)-Cys(Trt)-
peptidyl-resin was subjected to the general microwave-
assisted RCM procedure under the following conditions:
Resin-peptide (158 mg, 82.2 µmol), DCM (3 ml), LiCl/DMF
(0.4 M, 0.3 ml), second-generation Grubbs’ catalyst (7.0 mg,
8.2 µmol, 10 mol%), 100 °C, 1 h, 100% conversion into 7.
At the end of the reaction period, a small aliquot of
peptidyl-resin (∼1 mg) was subjected to the TFA-mediated
cleavage procedure. Mass spectral analysis of the iso-
lated residue confirmed the formation of the cyclic pep-
tide 7. Mass spectrum (ESI+, MeCN/H2O): m/z 769.4
[1/2(M + 2H)]+, 1/2(C69H94N20O17S2); m/z 1537.7 (M + H)+,
C69H93N20O17S2. LC-MS (Luna C8 RP-column, 10–60% MeOH
and 0.1% formic acid): tR = 8.59 min.
[2,8]-Dicarba-[3,12]-Cystino Conotoxin IMI
NH2-Gly-c[Hag-Cys-Ser-Asp-Pro-Arg-Hag]-Ala-Trp-Arg-
Cys-NH2 9. The resin-bound carbocyclic peptide (100 mg,
52.0 µmol) was swollen in DCM (3 × 1, 1 × 30 min) and DMF
(3 × 1, 1 × 30 min) and de-protected with 20% piperidine in
DMF (1 × 1, 2 × 20 min). The resin was then washed with
DMF (5 × 1 min), DCM (3 × 1 min), MeOH (3 × 1 min) and
dried on the SPPS manifold for 1 h. The Fmoc-de-protected
peptidyl-resin (47.0 mg, 24.4 µmol) was subjected to the TFA-
mediated cleavage procedure. The residue was then lyophilised
for 18 h to give the fully de-protected carbocyclic peptide as a
colourless solid (20.0 mg, 15.2 µmol). A sample of lyophilised
peptide (10.1 mg, 7.7 µmol) was dissolved in an aqueous
solution of (NH4)2CO3 (0.1 M, 80 ml) containing 5% DMSO
(4 ml). The reaction was stirred at room temperature and
monitored by the Ellman’s test [20]. After 3 days, the reac-
tion mixture was lyophilised and mass spectral analysis of
the isolated residue confirmed the formation of the cystine-
oxidised peptide 9. The peptide was purified by RP-HPLC
(Luna C8 RP-column, 10–60% MeOH and 0.1% formic acid)
and the unsaturated [2,8]-dicarba-[3,12]-cystino conotoxin
hybrid 9 was isolated as a colourless solid (1.8 mg, 5%) in
>99% purity. Mass spectrum (ESI+, MeCN/H2O): m/z 657.4
[1/2(M + 2H)]+, 1/2(C54H82N20O15S2); m/z 668.3 [1/2(M +
H + Na)]+, 1/2(C54H81N20NaO15S2); m/z 1313.5 (M + H)+,
C54H81N20O15S2. LC-MS (Luna C8 RP-column, 10–60% MeOH
and 0.1% formic acid): tR = 5.50 min.
[2,8]-Saturated Dicarba-[3,12]-Cystino Conotoxin IMI
NH2-Gly-c[Hag-Cys-Ser-Asp-Pro-Arg-Hag]-Ala-Trp-Arg-
Cys-NH2 2. The carbocyclic-Fmoc-Gly-Hag-Cys(Trt)-Ser
(OtBu)-Asp(OtBu)-Pro-Arg(Pbf)-Hag-Ala-Trp(Boc)-Arg(Pbf)-Cys
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(Trt)-peptidyl-resin was subjected to the general Wilkin-
son’s hydrogenation procedure under the following conditions:
Resin-peptide (200 mg, 0.14 mmol), DCM : MeOH (5 ml, 9 : 1),
Wilkinson’s catalyst (3 mg), 80 psi, 22 °C, 22 h. At the end
of the reaction period, a small aliquot of peptidyl-resin was
Fmoc-de-protected (20% piperidine in DMF, 1 × 1, 2 × 10 min)
and washed with DMF (5 × 1 min), DCM (5 × 1 min), MeOH
(5 × 1 min) and dried on the SPPS manifold for 1 h. The
Fmoc-de-protected peptidyl-resin was then subjected to the
TFA-mediated cleavage procedure. Mass spectral analysis of
the isolated residue indicated the presence of the cystine-
oxidised 2 form of the saturated product. Mass spec-
trum (ESI+, MeCN/H2O): m/z 658.3 [1/2(M + 2H)]+oxidised,
1/2(C54H84N20O15S2). LC-MS (Luna C8 RP-column, 10–60%
MeOH and 0.1% formic acid): tR 2 = 6.01 min.
[2,8]-Dicarba-[3,12]-Cystino Conotoxin
Transformations Linear [2,8]-Cys-[3,12]-Hag
Conotoxin IMI
Fmoc-Gly-Cys-Hag-Ser-Asp-Pro-Arg-Cys-Ala-Trp-Arg-
Hag-NH2 5. The linear peptide 5 was synthesised using the
general SPPS procedure outlined above with Rink amide resin
(730 mg, loading 0.52 mmol g−1, 0.38 mmol), NMM (250 µl,
2.27 mmol, 6 equiv.), the protected C-terminal amino acid,
Fmoc-L-Hag-OH (384 mg, 1.14 mmol, 3 equiv.) and HATU
(289 mg, 0.76 mmol, 2 equiv.) in DMF (3 ml). The mixture
was shaken gently for 2.5 h. At the end of the reaction period,
the resin-peptide was washed with DMF (7 ml, 3 × 1 min), de-
protected with 20% piperidine in DMF (7 ml, 1 × 1, 2 × 10 min)
and washed again with DMF (7 ml, 5 × 1 min). The above
procedure was repeated until the desired peptide sequence
was constructed. A small aliquot of the resin-peptide (∼1 mg)
was subjected to the TFA-mediated cleavage procedure and
mass spectral analysis confirmed the formation of the lin-
ear conotoxin analogue 5. Mass spectrum (ESI+, MeCN/H2O):
m/z 783.5 [1/2(M + 2H)]+, 1/2(C71H98N20O17S2); m/z 1565.7
(M + H)+, C71H97N20O17S2. LC-MS (Luna C8 RP-column,
10–60% MeOH and 0.1% formic acid): tR = 9.13 min.
[2,8]-Cys-[3,12]-Dicarba Conotoxin IMI
Fmoc-Gly-Cys-c[Hag-Ser-Asp-Pro-Arg-Cys-Ala-Trp-Arg-
Hag]-NH2 8. The linear Fmoc-Gly-Cys(Trt)-Hag-Ser(Ot
Bu)-Asp(OtBu)-Pro-Arg(Pbf)-Cys(Trt)-Ala-Trp(Boc)-Arg(Pbf)-
Hag-peptidyl-resin was subjected to the general microwave-
assisted RCM procedure under the following conditions:
Resin-peptide (840 mg, 0.44 mmol), DCM (5 ml), LiCl/DMF
(0.4 M, 0.5 ml), second generation Grubbs’ catalyst (74.3 mg,
87.5 µmol, 20 mol%), 100 °C, 1 h, 100% conversion into
8. At the end of the reaction period, a small aliquot
of peptidyl-resin (∼1 mg) was subjected to the TFA-
mediated cleavage procedure. Mass spectral analysis of
the isolated residue confirmed the formation of the cyclic
peptide 8. Mass spectrum (ESI+, MeCN/H2O): m/z 769.4
[1/2(M + 2H)]+, 1/2(C69H94N20O17S2); m/z 1537.7 (M + H)+,
C69H93N20O17S2. LC-MS (Luna C8 RP-column, 10–60% MeOH
and 0.1% formic acid): tR = 8.99 min.
[2,8]-Cystino-[3,12]-Dicarba Conotoxin IMI
Fmoc-Gly-Cys-c[Hag-Ser-Asp-Pro-Arg-Cys-Ala-Trp-Arg-
Hag]-NH2 10. The resin-bound carbocyclic peptide (100 mg,
52.0 µmol) was swollen in DCM (3 × 1, 1 × 30 min) and DMF
(3 × 1 min, 1 × 30 min) and de-protected with 20% piperidine
in DMF (1 × 1, 2 × 20 min). The resin was then washed with
DMF (5 × 1 min), DCM (3 × 1 min), MeOH (3 × 1 min) and
dried on the SPPS manifold for 1 h. The Fmoc-de-protected
peptidyl-resin (61.7 mg, 32.1 µmol) was subjected to the TFA-
mediated cleavage procedure. The residue was then lyophilised
for 18 h to give the fully de-protected carbocyclic peptide as a
colourless solid (15.1 mg, 11.5 µmol). A sample of lyophilised
peptide (11.2 mg, 8.5 µmol) was dissolved in an aqueous
solution of (NH4)2CO3 (0.1 M, 80 ml) containing 5% DMSO
(4 ml). The reaction was stirred at room temperature and
monitored by the Ellman’s test [20]. After 3 days, the reac-
tion mixture was lyophilised and mass spectral analysis of
the isolated residue confirmed the formation of the cystine-
oxidised peptide 10. The peptide was purified by RP-HPLC
(Luna C8 RP-column, 10–60% MeOH and 0.1% formic acid)
and the unsaturated [2,8] -cystino- [3,12] -dicarba conotoxin
hybrid 10 was isolated as a colourless solid (2.3 mg, 5%) in
>99% purity. Mass spectrum (ESI+, MeCN/H2O): m/z 657.3
[1/2(M + 2H)]+, 1/2(C54H82N20O15S2); m/z 668.3 [1/2(M +
H + Na)]+, 1/2(C54H81N20NaO15S2); m/z 1313.6 (M + H)+,
C54H81N20O15S2. LC-MS (Luna C8 RP-column, 10–60% MeOH
and 0.1% formic acid): tR = 4.46 min.
[2,8]-Cystino-[3,12]-Saturated Dicarba Conotoxin IMI
Fmoc-Gly-Cys-c[Hag-Ser-Asp-Pro-Arg-Cys-Ala-Trp-Arg-
Hag]-NH2 3. The carbocyclic-Fmoc-Gly-Cys(Trt)-Hag-Ser
(OtBu)-Asp(OtBu)-Pro-Arg(Pbf)-Cys(Trt)-Ala-Trp(Boc)-Arg(Pbf)-
Hag-peptidyl-resin was subjected to the general Wilkin-
son’s hydrogenation procedure under the following con-
ditions: Resin-peptide (200 mg, 0.14 mmol), DCM : MeOH
(5 ml, 9 : 1), Wilkinson’s catalyst (3 mg), 80 psi, 22 °C, 18 h.
At the end of the reaction period, a small aliquot of
peptidyl-resin was Fmoc-de-protected (20% piperidine in
DMF, 1 × 1, 2 × 10 min) and washed with DMF (5 × 1 min),
DCM (5 × 1 min), MeOH (5 × 1 min) and dried on the
SPPS manifold for 1 h. The Fmoc-de-protected peptidyl-
resin was then subjected to the TFA-mediated cleavage
procedure. Mass spectral analysis of the isolated residue
indicated the presence of the cystine-oxidised 3 form of
the saturated product. Mass spectrum (ESI+, MeCN/H2O):
m/z 658.4 [1/2(M + 2H)]+oxidised, 1/2(C54H84N20O15S2); m/z
1315.7 (M + H)+oxidised, C54H83N20O15S2. LC-MS (Luna C8
RP-column, 10–60% MeOH and 0.1% formic acid): tR 3 =
7.02 min.
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